Related Experiment Video
Updated: May 21, 2026

10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
New drugs to treat tuberculosis
1University of Nebraska Medical Center, 988106 Nebraska Medical Center Omaha, NE 68198-8106 USA.
F1000 Medicine Reports
|June 22, 2012
Summary
Tuberculosis treatment remains challenging due to lengthy regimens and complex global factors. Recent advancements offer new hope for developing improved diagnostics and therapeutics for active tuberculosis.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Tuberculosis (TB) remains a significant global health threat, causing numerous deaths annually.
- Current TB therapies are effective but require prolonged and difficult treatment durations.
- Control efforts are hampered by inadequate public health systems, the co-epidemic of TB and HIV, and rising drug resistance.
Purpose of the Study:
- To review novel strategies for developing tuberculosis treatment regimens.
- To highlight new and repurposed anti-TB agents currently in clinical development.
- To focus on advancements in treating active tuberculosis.
Main Methods:
- Literature review of recent advancements in TB treatment development.
- Analysis of new pathways for TB regimen design.
- Survey of anti-TB agents in various phases of clinical trials.
Main Results:
- Significant progress is being made in TB diagnostics and therapeutics after a period of stagnation.
- New approaches to regimen development are emerging.
- Several novel and repurposed drugs are advancing through clinical development.
Conclusions:
- Despite challenges, the pipeline for TB therapeutics is strengthening.
- These developments offer potential for more effective and manageable tuberculosis treatments.
- Continued research and development are crucial for combating the global TB burden.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

